BY RESEARCH & FOCUS AREAS

Advances and challenges in cancer immunoprevention and immune interception
Stanton, S. E., Castle, P. E., Finn, O. J., Sei, S. & Emens, L. A., Mar 21 2024, In: Journal for ImmunoTherapy of Cancer. 12, 3
Research output: Contribution to journal › Review article › peer-review

Open Access
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
Beckermann, K. E., Bestvina, C. M., El Osta, B., Sanborn, R. E., Borghaei, H., Lammers, P. E., Selvaggi, G., Whisenant, J. G., Heimann-Nichols, E., Berry, L., Hsu, C. Y., Shyr, Y., Horn, L. & Wakelee, H., Feb 2024, In: JTO Clinical and Research Reports. 5, 2, 100619.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators, Jan 6 2024, In: The Lancet. 403, 10421, p. 31-43 13 p.
Research output: Contribution to journal › Article › peer-review
9 Scopus citations

Research & Focus Areas